Companion Medical Secures $27.5 Million Debt Financing from K2 HealthVentures
Companion Medical, Inc., an innovative diabetes company that developed the first and only FDA-cleared smart insulin pen and app system, today announced that it has entered into a loan and security agreement for up to $27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
"This financing enhances our financial flexibility as we continue to scale commercialization of our flagship product - InPen," said Sean Saint, chief executive officer of Companion Medical. "The K2HV team has a strong understanding of our innovative approach to diabetes management and the high-impact solution that InPen represents for people living with this disease. We are pleased to be able to partner with them on this transaction in support of our growth."